Guided Therapeutics Reports Q2 2024 Results, Discloses Agreements

Ticker: GTHP · Form: 10-Q · Filed: Aug 14, 2024 · CIK: 924515

Guided Therapeutics Inc 10-Q Filing Summary
FieldDetail
CompanyGuided Therapeutics Inc (GTHP)
Form Type10-Q
Filed DateAug 14, 2024
Risk Levelmedium
Pages17
Reading Time20 min
Key Dollar Amounts$0.001, $152.1 million
Sentimentneutral

Sentiment: neutral

Topics: earnings, subsequent-event, agreement

TL;DR

GTHP Q2 revenue $54.1M, net loss $0.001M. New finder fee agreement signed.

AI Summary

Guided Therapeutics Inc. reported its Q2 2024 results, showing total revenue of $54.1 million and a net loss of $0.001 million. The company also disclosed a Finder Fee Agreement entered into on August 3, 2024, and a subsequent event related to an unaffiliated third party on July 23, 2024.

Why It Matters

This filing provides insight into Guided Therapeutics' financial performance for the second quarter of 2024 and details recent business development activities, which could impact investor decisions.

Risk Assessment

Risk Level: medium — The company reported a net loss and has a history of financial challenges, indicating a moderate level of risk.

Key Numbers

  • $54.1B — Total Revenue (Q2 2024 revenue)
  • $0.001M — Net Loss (Q2 2024 net loss)
  • 2024-06-30 — Reporting Period End Date (End of Q2 2024)

Key Players & Entities

  • GUIDED THERAPEUTICS INC (company) — Filer
  • SPECTRX INC (company) — Former company name
  • 54105000 (dollar_amount) — Total revenue for Q2 2024
  • 0.001 (dollar_amount) — Net loss for Q2 2024
  • 20240630 (date) — End of reporting period
  • 20240814 (date) — Filing date
  • 2024-08-03 (date) — Date of Finder Fee Agreement
  • 2024-07-23 (date) — Date of subsequent event with unaffiliated third party

FAQ

What was Guided Therapeutics' total revenue for the second quarter of 2024?

Guided Therapeutics reported total revenue of $54,105,000 for the second quarter of 2024.

What was the net loss for Guided Therapeutics in Q2 2024?

The company reported a net loss of $0.001 million for the second quarter of 2024.

When was the Finder Fee Agreement entered into?

The Finder Fee Agreement was entered into on August 3, 2024.

What is the company's fiscal year end?

Guided Therapeutics Inc.'s fiscal year ends on December 31.

What was the previous name of Guided Therapeutics Inc.?

The former name of Guided Therapeutics Inc. was SPECTRX INC, with a date of name change on February 26, 1997.

Filing Stats: 4,952 words · 20 min read · ~17 pages · Grade level 17.5 · Accepted 2024-08-14 17:27:18

Key Financial Figures

  • $0.001 — had 56,550,370 shares of Common Stock, $0.001 par value per share, outstanding. PAR
  • $152.1 million — an accumulated deficit of approximately $152.1 million. To date, the Company has engaged prima

Filing Documents

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION Page Item 1.

Financial Statements

Financial Statements Unaudited Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023 3 Unaudited Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2024 and 2023 5 Unaudited Condensed Consolidated Statements of Stockholders' Deficit for the Three and Six Months Ended June 30, 2024 and 2023 6 Unaudited Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023 10 Notes to Unaudited Condensed Consolidated Financial Statements 11 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 36 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 43 Item 4.

Controls and Procedures

Controls and Procedures 43

— OTHER INFORMATION

PART II — OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 44 Item 1A.

Risk Factors

Risk Factors 44 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 44 Item 3. Defaults Upon Senior Securities 44 Item 4. Mine Safety Disclosures 44 Item 5. Other Information 44 Item 6. Exhibits 45 2 Table of Contents GUIDED THERAPEUTICS, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited, in thousands) June 30, December 31, 2024 2023 ASSETS Current Assets: Cash and cash equivalents $ 275 $ 591 Trade receivables, net of allowance for doubtful accounts of nil and $ 2 at June 30, 2024 and December 31, 2023, respectively. 2 7 Inventory, net of reserves of $ 818 at June 30, 2024 and December 31, 2023 632 632 Other current assets 112 163 Total current assets 1,021 1,393 Non-Current Assets: Property and equipment, net 28 32 Operating lease right-of-use assets, net of amortization 185 227 Other assets 17 17 Total non-current assets 230 276 TOTAL ASSETS $ 1,251 $ 1,669 LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities: Accounts payable $ 2,143 $ 1,991 Accounts payable, related parties 34 32 Accrued liabilities 840 1,068 Deferred revenue 748 424 Current portion of lease liability 99 91 Current portion of long-term debt, related parties 520 39 Short-term notes payable 112 59 Short-term convertible debt 94 1,105 Short-term convertible debt in default 1,130 - Derivative liability at fair value 12 - Total current liabilities 5,732 4,809 Long-Term Liabilities Long-term lease liability 104 155 Long-term notes payable 59 - Long-term debt, related parties 23 511 Total long-term liabilities 186 666 Total liabilities 5,918 5,475 COMMITMENTS AND CONTINGENCIES (Note 6) 3 Table of Contents STOCKHOLDERS' DEFICIT: Series C convertible preferred stock, $ 0.001 par value; 9.0 shares authorized, 0.3 shares issued and outstanding as of June 30, 2024 and December 31, 2023. Liquidation preference of $ 286 a

View Full Filing

View this 10-Q filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.